Just days after announcing its merger with Launch One Acquisition Corp., Israeli biotech firm Minovia Therapeutics has achieved a critical milestone: the US Food and Drug Administration (FDA) has granted Fast Track and Rare Pediatric Disease (RPD) designations to the company’s lead investigational therapy, MNV-201.
Dual recognition significantly strengthens the clinical and regulatory path for the mitochondrial cell therapy, which is currently in Phase II trials for Pearson Syndrome, a rare and life-threatening pediatric mitochondrial disorder.
“Both Fast Track and Rare Pediatric Disease designations are critical milestones for Minovia,” said Natalie Yivgi-Ohana, co-founder and CEO of Minovia. “They validate our scientific approach and highlight the urgent need for therapeutic options in Pearson Syndrome, while offering potential benefits that can help reduce time to market and support the overall clinical and commercial strategy.”
Speeding Toward Market
The FDA’s Fast Track Designation is reserved for drugs that address serious or life-threatening conditions with unmet medical needs. It allows for increased engagement with the FDA, eligibility for priority review, and the possibility of submitting a Biologics License Application (BLA) on a rolling basis — all of which can streamline the development and approval process.
The Rare Pediatric Disease Designation, meanwhile, opens the door for Minovia to potentially receive a Pediatric Priority Review Voucher (PRV) if MNV-201 is approved. These vouchers are highly sought after, granting expedited review of a future drug application. Though currently on hold pending reauthorization by Congress, these vouchers have historically sold for over $100 million in the secondary market.
MNV-201 is currently being studied in an FDA-cleared, Phase II clinical trial in patients with Pearson Syndrome. The company expects to finalize plans for a pivotal trial in consultation with the FDA and anticipates launching registrational studies in 2026.
How MNV-201 Works
Pearson Syndrome is an ultra-rare disorder caused by large-scale deletions in mitochondrial DNA. These deletions impair the energy-producing function of cells, leading to severe symptoms such as bone marrow failure, metabolic crises, and multi-organ dysfunction. There are no approved treatments, and most patients die in childhood, relying only on supportive care.
MNV-201 is based on Minovia’s Mitochondrial Augmentation Technology, which involves transferring healthy mitochondria into a patient’s own stem cells. In early-stage trials, the therapy has shown a favorable safety profile and encouraging signs of multi-system benefit, including improved growth, muscle function, and hematologic stability.
Minovia is also exploring MNV-201 in other indications, including low-risk myelodysplastic syndrome (MDS), a chronic blood disorder associated with aging. The company has launched compassionate use programs in neurological mitochondrial disorders and is laying the groundwork for future longevity-focused applications of MAT.
Merger To Fuel Growth
The FDA milestone arrives just days after Minovia announced its proposed merger with Launch One Acquisition Corp., a special purpose acquisition company (SPAC) listed on Nasdaq. The combined entity, to be named Mito US One Ltd., is expected to go public in the fourth quarter of 2025.
The transaction assigns Minovia a pre-money valuation of $180 million and includes provisions for additional financing: a $5 million bridge round, a $57.5 million earnout in equity, and an anticipated $18 million in PIPE (private investment in public equity) financing. Launch One’s trust currently holds approximately $239.7 million, a portion of which may further boost Minovia’s capital depending on shareholder redemptions.
These funds will be used to drive clinical development, advance regulatory interactions, and prepare for the commercial launch of MAT-based longevity treatments through global clinic partnerships starting in 2026.
“Minovia is pioneering a new category of mitochondrial therapy that targets the root cause of disease and aging — mitochondrial failure,” said Yivgi-Ohana. “With compelling early clinical data, regulatory momentum, and an expanding pipeline, we are poised to transform care across rare diseases and the longevity sector.”
Broad Pipeline And Longevity Vision
Beyond Pearson Syndrome, Minovia is testing MNV-201 in other indications, including low-risk myelodysplastic syndrome (MDS), a chronic blood disorder associated with aging. The company has also launched compassionate use programs in neurological mitochondrial conditions. Across its pipeline, MAT has shown consistent safety, multi-organ benefits, and biomarker-based signs of mitochondrial restoration.
Minovia aims to commercialize its MAT-based therapies not only through traditional drug development channels but also via global partnerships with longevity clinics, with a launch targeted for 2026.
By targeting the fundamental driver of mitochondrial dysfunction, Minovia positions itself at the intersection of rare disease innovation and the expanding longevity biotech market.
The next key milestones include finalizing the pivotal trial design with the FDA, securing the PRV pending Congressional reauthorization, and closing the merger transaction in Q4 2025. If successful, Minovia could become a key player in both mitochondrial medicine and the longevity space.
As Dr. Yivgi-Ohana summed it up: “Our research has already demonstrated durable safety and life-changing impact. Supported by clinical data, FDA Fast Track Designation, and a clear path to pivotal trial, we believe our MAT platform is uniquely positioned to drive value across both rare disease and the fast-growing longevity market.”
